<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573660</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10349</org_study_id>
    <nct_id>NCT04573660</nct_id>
  </id_info>
  <brief_title>Abbott Vascular Medical Device Registry</brief_title>
  <acronym>AV-MDR</acronym>
  <official_title>Abbott Vascular Medical Device Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose&#xD;
      of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the&#xD;
      devices in scope within their intended use with the aim of confirming safety and performance&#xD;
      throughout their expected lifetime, ensuring the continued acceptability of identified risks,&#xD;
      detecting emerging risks on the basis of factual evidence, ensuring the continued&#xD;
      acceptability of the benefit-risk ratio, and identifying possible systematic misuse or&#xD;
      off-label usage such that the intended use can be verified as appropriate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2020</start_date>
  <completion_date type="Anticipated">November 2031</completion_date>
  <primary_completion_date type="Anticipated">November 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, amputation, and TLR</measure>
    <time_frame>During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)</time_frame>
    <description>Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, amputation, and TLR</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, amputation, and TLR</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion</measure>
    <time_frame>During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)</time_frame>
    <description>Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of potential complications (Implant success, occlusion success,migration)</measure>
    <time_frame>During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)</time_frame>
    <description>Composite of potential complications including implant success, occlusion success, migration will be assessed among the patients who receive AVP or AVP II or AVP 4 and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of occlusion success and migration</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of occlusion success and migration will be assessed among the patients who receive AVP or AVP II or AVP 4 and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of vessel dissection, perforation, and thromboembolism</measure>
    <time_frame>During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)</time_frame>
    <description>Composite of vessel dissection, perforation, and thromboembolism during procedure will be assessed among the patients who receive PressureWire X and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with signal drift (Signal drift between measurements (Pd/Pa** pressure drift &gt;0.03; &lt;0.97 or &gt;1.03)</measure>
    <time_frame>During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)</time_frame>
    <description>Signal drift (Signal drift between measurements (Pd/Pa** pressure drift &gt;0.03; &lt;0.97 or &gt;1.03) will be assessed among the patients who receive PressureWire X and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Loss of capture</measure>
    <time_frame>During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)</time_frame>
    <description>Loss of capture (average time of loss of capture across patients) will be assessed among the patients who receive Pacel FDPC and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation)</measure>
    <time_frame>During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)</time_frame>
    <description>Composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation) will be assessed among the patientswho receive Pacel BPC and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)</measure>
    <time_frame>During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)</time_frame>
    <description>Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.</description>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">3784</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Symptomatic Ischemic Heart Disease</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Restenoses, Coronary</condition>
  <condition>Coronary Artery Lesions</condition>
  <condition>Venous Embolism</condition>
  <condition>Arterial Embolism</condition>
  <arm_group>
    <arm_group_label>XIENCE PRIME BTK</arm_group_label>
    <description>Participants in the XIENCE PRIME BTK arm will receive XIENCE PRIME BTK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Absolute Pro LL</arm_group_label>
    <description>Participants in the Absolute Pro LL arm will receive Absolute Pro LL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supera 7.5 Outer Diameter (OD)</arm_group_label>
    <description>Participants in the Supera 7.5 OD arm will receive Supera 7.5 OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xpert Pro</arm_group_label>
    <description>Participants in the Xpert Pro arm will receive Xpert Pro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pacel Pacing Catheters</arm_group_label>
    <description>Participants in the Pacel Pacing Catheters arm will receive Pacel Pacing Catheters (pacel bipolar pacing catheter [BPC] or pacel flow directed bipolar pacing catheter [FDPC])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplatzer Vascular Plugs</arm_group_label>
    <description>Participants in the Amplatzer Vascular Plugs (AVP) arm will receive Amplatzer Vascular Plugs (AVP I/ AVP II/ AVP 4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pressure Wire</arm_group_label>
    <description>Participants in the Pressure Wire arm will receive Pressure Wire X</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multilink BMS</arm_group_label>
    <description>Participants in the Multilink BMS arm will receive either MULTI-LINK 8/ MULTILINK 8 Long Length (LL)/ MULTILINK 8 Small Vessel (SV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE PRIME BTK stent</intervention_name>
    <description>The participants in the XIENCE PRIME BTK arm will receive XIENCE PRIME BTK stent or its competitors/alternative therapies</description>
    <arm_group_label>XIENCE PRIME BTK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absolute Pro LL stent</intervention_name>
    <description>The participants in the Absolute Pro LL arm will receive Absolute Pro LL stent or its competitors/alternative therapies</description>
    <arm_group_label>Absolute Pro LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supera 7.5 OD stent</intervention_name>
    <description>The participants in the Supera 7.5 OD arm will receive Supera 7.5 OD stent or its competitors/alternative therapies</description>
    <arm_group_label>Supera 7.5 Outer Diameter (OD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xpert Pro stent</intervention_name>
    <description>The participants in the Xpert Pro arm will receive Xpert Pro stent or its competitors/alternative therapies</description>
    <arm_group_label>Xpert Pro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacel BPC</intervention_name>
    <description>The participants in the Pacel Pacing Catheters will receive either Pacel BPC or Pacel FDPC or its competitors/alternative therapies</description>
    <arm_group_label>Pacel Pacing Catheters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacel FDPC</intervention_name>
    <description>The participants in the Pacel Pacing Catheters will receive either Pacel FDPC or Pacel BPC or its competitors/alternative therapies</description>
    <arm_group_label>Pacel Pacing Catheters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVP I</intervention_name>
    <description>The participants in the Amplatzer Vascular Plugs will receive either AVP I/ AVP II/ AVP 4 or its competitors/alternative therapies</description>
    <arm_group_label>Amplatzer Vascular Plugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVP II</intervention_name>
    <description>The participants in the Amplatzer Vascular Plugs will receive either AVP II/ AVP I/ AVP 4 or its competitors/alternative therapies</description>
    <arm_group_label>Amplatzer Vascular Plugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVP 4</intervention_name>
    <description>The participants in the Amplatzer Vascular Plugs will receive either AVP 4/ AVP I/ AVP II or its competitors/alternative therapies</description>
    <arm_group_label>Amplatzer Vascular Plugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PressureWire X</intervention_name>
    <description>The participants in the Pressure Wire will receive PressureWire X or its competitors/alternative therapies</description>
    <arm_group_label>Pressure Wire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MULTI-LINK 8 stent</intervention_name>
    <description>The participants in the Multilink BMS arm will receive either MULTI-LINK 8 stent/ MULTI-LINK 8 LL/ MULTILINK 8 SV or its competitors/alternative therapies</description>
    <arm_group_label>Multilink BMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MULTI-LINK 8 LL stent</intervention_name>
    <description>The participants in the Multilink BMS arm will receive either MULTI-LINK 8 LL stent/ MULTI-LINK 8 stent/MULTI-LINK 8 SV or its competitors/alternative therapies</description>
    <arm_group_label>Multilink BMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MULTI-LINK 8 SV stent</intervention_name>
    <description>The participants in the Multilink BMS arm will receive either MULTI-LINK 8 SV stent/ MULTI-LINK 8 stent/ MULTI-LINK 8 LL or its competitors/alternative therapies</description>
    <arm_group_label>Multilink BMS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll subjects 18 years and older of all genders in which at least one&#xD;
        Abbott device specified in the CIP and/or similar competitive device is used. Patients must&#xD;
        meet all general eligibility criteria and provide written informed consent prior to sites'&#xD;
        collection of patient data for the investigation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 18 years of age.&#xD;
&#xD;
          2. Subject has a planned procedure, or underwent a procedure, that will use/used one or&#xD;
             more Abbott or competitive devices covered in this registry.&#xD;
&#xD;
          3. Subject is willing and able to comply with, or has already completed, the follow-up&#xD;
             schedule specified in this protocol.&#xD;
&#xD;
          4. Subject must provide written informed consent prior to any clinical&#xD;
             investigation-related data collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly&#xD;
        spreading novel infectious agent within the prior 2 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinuta Rau, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Devices</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Latania Chura</last_name>
    <phone>+1 503-380-8623</phone>
    <email>latania.chura@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Standley</last_name>
    <phone>+1 408-845-0963</phone>
    <email>robert.standley@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital - Univ. of Alabama at Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Mustafa Ahmed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Somjot Brar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James D Flaherty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Konstantinos Boudoulas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis Campus Aalst</name>
      <address>
        <city>Aalst</city>
        <state>Eflndrs</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lieven Maene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius Ziekenhuis</name>
      <address>
        <city>Dendermonde</city>
        <state>Eflndrs</state>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Koen Deloose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum am Bethanien Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Piorkowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNIVERSITATSMEDIZIN der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhinela</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. med. Christine Espinola-Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AÖR</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. med. Dierk Scheinert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schlesw</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Matthias Lutz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bela Merkely</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Kahlberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Antonio Bartorelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan-Peter Van Kuijk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalon</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sergi Bellmunt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital - University Hospital of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Iris Baumgartner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <state>Mtaiwan</state>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wen Lieng Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Ntaiwan</state>
        <zip>106</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chi-Hung Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <state>Staiwan</state>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cheng-Han Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital</name>
      <address>
        <city>Tainan City</city>
        <state>Staiwan</state>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhih-Cherng Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Al Qassimi Hospital</name>
      <address>
        <city>Sharjah</city>
        <zip>3500</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arif Al Nooryani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Arab Emirates</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XIENCE Prime below the knee (BTK)</keyword>
  <keyword>Absolute Pro</keyword>
  <keyword>ABT-CIP-10349</keyword>
  <keyword>Supera</keyword>
  <keyword>Xpert Pro</keyword>
  <keyword>Pacel Pacing Catheters</keyword>
  <keyword>Amplatzer Vascular Plugs</keyword>
  <keyword>Pressure Wire</keyword>
  <keyword>MULTI-LINK bare metal stents (BMS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

